Table 1 Serologic and global assessment parameters in patients with adult-onset Still's disease receiving 5 mg/kg infliximab
From: Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases
| Â | Baseline (mean) | 8 weeks (mean) |
|---|---|---|
C-reactive protein (mg/dL) | 65 | 5 |
Erythrocyte sedimentation rate (mm/h) | 53 | 16 |
Serum ferritin (mg/dL) | 2952 | 58 |
Tender joint count | 15 | 2.7 |
Swollen joint count | 9 | 1.8 |